3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
3
Phase NA
2
Phase 4
2
Phase EARLY_PHASE1
1
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Head & Neck
4
Thoracic
2
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Breast
1
Conditions
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Dacarbazine
27
Nivolumab
26
pembrolizumab
22
Ipilimumab
20
3-ingenyl angelate
11
Interferon-alpha
10
Imiquimod
10
Temozolomide
9
trametinib
8
Vemurafenib
8
Photochemotherapy
8
Aminolevulinic Acid
8
methyl 5-aminolevulinate
7
dabrafenib
7
cemiplimab
7
aldesleukin
7
Introns
7
Surgical Procedures, Operative
6
Radiotherapy
6
Interferon alpha-2
6
Fluorouracil
6
Paclitaxel
5
Melphalan
5
Interleukin-2
5
Cisplatin
5
Chemotherapy, Adjuvant
5
talimogene laherparepvec
4
binimetinib
4
Specimen Handling
4
Opdualag
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Immune Checkpoint Inhibitors
×
Dermatologic
×
Clear all
NCT05522660
2026-04-27
USZ-STRIKE
ETOP IBCSG Partners Foundation
Phase 3
Recruiting
180 enrolled